- In January 2025, The NHS in England began offering liquid biopsies to women with mutated breast cancer, facilitating access to new life-extending treatments designed to target specific genetic mutations. This advancement allows for real-time monitoring of tumor evolution and treatment resistance, marking a significant step forward in precision medicine for breast cancer patients
- In October 2024, The U.K. government announced funding for a £120 blood test capable of detecting 12 common cancers, including breast cancer, before symptoms appear. Developed by researchers at the University of Southampton, this PCR-based test aims to revolutionize early cancer detection and treatment, potentially improving survival rates through earlier intervention
- In November 2024, Illumina, Inc. launched version 2 of the TruSight Oncology 500 ctDNA kit, enhancing the precision of genomic profiling for solid tumors, including breast cancer. This updated assay offers faster results with improved analytical sensitivity, aiding in the detection of drug resistance and monitoring of tumor progression
- In December 2024, Guardant Health, Inc. partnered with Susan G. Komen to develop clinical studies aimed at identifying early-stage breast cancer patients using Guardant Reveal, a blood-based test. This collaboration focuses on improving early detection and personalized treatment strategies for breast cancer patients
Frequently Asked Questions
Companies such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), Agilent Technologies Inc. (U.S.), Merck KGaA (Germany), QIAGEN (Germany), Abcam plc. (U.K.), Cell Signaling Technology Inc. (U.S.), are the major companies in the breast cancer liquid biopsy market.
In November 2024, Illumina, Inc. launched version 2 of the TruSight Oncology 500 ctDNA kit, enhancing the precision of genomic profiling for solid tumors, including breast cancer. In November 2024, Bio-Rad Laboratories introduced its ddPCR Breast Cancer Panel, a highly sensitive digital PCR-based liquid biopsy assay designed for the detection and monitoring of key breast cancer mutations, improving early diagnosis and treatment selection.
The countries covered in the breast cancer liquid biopsy market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
